Skip to content
2000
Volume 2, Issue 1
  • ISSN: 2666-6499
  • E-ISSN: 2666-6502

Abstract

Introduction

Probiotics have proven to have a strong potential for treating and/or preventing a wide range of diseases and also aid in maintaining a healthy gut microbial ecology and are effective against pathogens that are resistant to many drugs. As a result, the probiotics industry is expanding fast on a global scale, and research to explore probiotics into medicinal adjuvants has been intensified across the globe. However, due to the lack of an attractive dosage form, probiotics are not very compliant among patients. The present study aimed to formulate fizzy granules of probiotics () by involving the concept of quality by design for industrial acceptance.

Methods

For this, critical formulation attributes and various risks involved during the formulation have been identified through the Ishikawa fishbone diagram and risk assessment studies in compliance with relevant ICH guidelines. Selected significant variables involved during the formulation were further analyzed through a central composite design to analyze the optimum level of variables. Further, 2D contour plots and 3D response surface plots have been designed to define the relationship between the quality attributes and input variables.

Results and Discussion

The developed statistical model was further validated and found appropriate to define the quality parameters at an acceptable level. Final quality profiling of the developed probiotics fizzy granules was performed to validate compliance with the quality target product profile and results were found to be satisfactory.

Conclusion

This study involved the development of a novel fizzy probiotic formulation, incorporating the concept of quality by design to enhance acceptance among patients, pharmaceutical companies, and regulatory bodies.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/probiot/10.2174/0126666499346209250214075754
2025-04-11
2025-11-01

  • From This Site

    /content/journals/probiot/10.2174/0126666499346209250214075754
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. LiebermanH. LachmanL. SchwartzJ.B. Pharmaceutical Dosage Forms: Tablets.MARCEL DEKKER, INCNew York1989Vol. 1
     [Google Scholar]
  2. DouroumisD. Orally disintegrating dosage forms and taste-masking technologies; 2010.Expert Opin. Drug Deliv.20118566567510.1517/17425247.2011.56655321438776
     [Google Scholar]
  3. SrinathK.R. ChowdaryC.P. PalanisamyP. KrishnaA.V. AparnaS. Formulation and evaluation of effervescent tablets of paracetamol.Int J Pharm Res Dev.20113376104
     [Google Scholar]
  4. DiyyaA. ThomasN.V. Formulation and evaluation of Metronidazole effervescent granules.Int. J. Pharm. Sci. Res.20189625252529
     [Google Scholar]
  5. MasaadAMA MaghrabiIA Formulation of a newly effervescent paracetamol tablets.2017Available from: https://www.semanticscholar.org/paper/Formulation-of-a-newly-effervescent-paracetamol-Masaad-Maghrabi/f23127b1daf25e10895ed281e1291bf7187c1bb8
  6. TekadeB.W. JadhaoU.T. ThakareV.M. BhortakeL.R. Formulation and evaluation of diclofenac sodium effervescent tablet.Infrared Spectroscopy.201491011
     [Google Scholar]
  7. AslaniA. SharifianT. Formulation, characterization and physicochemical evaluation of amoxicillin effervescent tablets.Adv. Biomed. Res.20143120910.4103/2277‑9175.14325225371866
     [Google Scholar]
  8. MontonC. SuksaereeJ. PathompakP. Can makjong (Scaphium macropodum) powder formed gel in effervescent blend.Int. J. Pharm. Pharm. Sci.201466610612
     [Google Scholar]
  9. AslaniA. FattahiF. Formulation, characterization and physicochemical evaluation of potassium citrate effervescent tablets.Adv. Pharm. Bull.20133121722524312839
     [Google Scholar]
  10. KaushikD. DurejaH. SainiT.R. Formulation and evaluation of olanzapine mouth dissolving tablets by effervescent formulation approach.INDIAN DRUGS-BOMBAY200441410412
     [Google Scholar]
  11. BhattacharyyaS. SwethaG. Formulation and evaluation of effervescent granules of Fexofenadine hydrochloride.Pharma Innov.201433, Part A1
     [Google Scholar]
  12. PatelJ.B. SuhagiaB.N. PatelM.N. PatelB.T. PatelA.M. PatelT.R. Preparation and evaluation of effervescent tablets of ibuprofen.WJPPS20132421452155
     [Google Scholar]
  13. PatelS.G. SiddaiahM. Formulation and evaluation of effervescent tablets: A review.J. Drug Deliv. Ther.20188629630310.22270/jddt.v8i6.2021
     [Google Scholar]
  14. KumarS. AshishB. Formulation by Design Approach for Fizzy Granules Using Statistical Optimization Methodologies.Asian J. Pharm.201594S59
     [Google Scholar]
  15. BanerjeeN. SinghS. Formulation, evaluation and optimization of effervescent granules to be reconstituted into suspension of levetiracetam for sustained release.Int. J. Pharm. Sci. Rev. Res.2013202181186
     [Google Scholar]
  16. KimW.S. HanG.G. HongL. KangS.K. ShokouhimehrM. ChoiY.J. ChoC.S. Novel production of natural bacteriocin via internalization of dextran nanoparticles into probiotics.Biomaterials201921811936010.1016/j.biomaterials.2019.11936031336278
     [Google Scholar]
  17. Mousavi KhaneghahA. AbhariK. EşI. SoaresM.B. OliveiraR.B.A. HosseiniH. RezaeiM. BalthazarC.F. SilvaR. CruzA.G. RanadheeraC.S. Sant’AnaA.S. Interactions between probiotics and pathogenic microorganisms in hosts and foods: A review.Trends Food Sci. Technol.20209520521810.1016/j.tifs.2019.11.022
     [Google Scholar]
  18. MombelliB. GismondoM.R. The use of probiotics in medical practice.Int. J. Antimicrob. Agents200016453153610.1016/S0924‑8579(00)00322‑811118874
     [Google Scholar]
  19. SandersM.E. Probiotics: considerations for human health.Nutr. Rev.2003613919910.1301/nr.2003.marr.91‑9912723641
     [Google Scholar]
  20. AroraM. SharmaS. BaldiA. Comparative insight of regulatory guidelines for probiotics in USA, India and Malaysia: A critical review.Int. J. Biotechnol. Wellness Ind.2013225164
     [Google Scholar]
  21. DoronS. GorbachS.L. Probiotics: their role in the treatment and prevention of disease.Expert Rev. Anti Infect. Ther.20064226127510.1586/14787210.4.2.26116597207
     [Google Scholar]
  22. TeughelsW. Van EsscheM. SliepenI. QuirynenM. Probiotics and oral healthcare.Periodontol. 2000200848111114710.1111/j.1600‑0757.2008.00254.x18715361
     [Google Scholar]
  23. SenM. Role of probiotics in health and disease: A review.J. Pak. Med. Assoc.2013632253257
     [Google Scholar]
  24. HemaiswaryaS. RajaR. RavikumarR. CarvalhoI.S. Mechanism of action of probiotics.Braz. Arch. Biol. Technol.201356111311910.1590/S1516‑89132013000100015
     [Google Scholar]
  25. KerryR.G. PatraJ.K. GoudaS. ParkY. ShinH-S. DasG. Benefaction of probiotics for human health: A review.Yao Wu Shi Pin Fen Xi201826392793929976412
     [Google Scholar]
  26. BhoopB.S. Quality by Design (QbD) for holistic pharma excellence and regulatory compliance.Pharm. Times20144682633
     [Google Scholar]
  27. SharmaS. AroraM. BaldiA. Probiotics in India: Current status and future prospects.Pharm Aspire.20131112
     [Google Scholar]
  28. VogtF.G. KordA.S. Development of quality-by-design analytical methods.J. Pharm. Sci.2011100379781210.1002/jps.2232521280050
     [Google Scholar]
  29. KovácsB. PéterfiO. Kovács-DeákB. Székely-SzentmiklósiI. FülöpI. BábaL.I. BodaF. Quality-by-design in pharmaceutical development: From current perspectives to practical applications.Acta Pharm.202171449752610.2478/acph‑2021‑003936651549
     [Google Scholar]
  30. HallA. Experimental design: Design experimentation.Des. Issues2011272172610.1162/DESI_a_00074‑Hall
     [Google Scholar]
  31. FranceschiniG. MacchiettoS. Model-based design of experiments for parameter precision: State of the art.Chem. Eng. Sci.200863194846487210.1016/j.ces.2007.11.034
     [Google Scholar]
  32. JainS. Quality by design (QBD): A comprehensive understanding of implementation and challenges in pharmaceuticals development.Int. J. Pharm. Pharm. Sci.2014612935
     [Google Scholar]
  33. MishraV. ThakurS. PatilA. ShuklaA. Quality by design (QbD) approaches in current pharmaceutical set-up.Expert Opin. Drug Deliv.201815873775810.1080/17425247.2018.150476830044646
     [Google Scholar]
  34. ShivhareM. McCreathG. Practical considerations for DoE implementation in quality by design.Bioprocess Int.2010862230
     [Google Scholar]
  35. ThakorN.S. AmrutkarS.V. Implementing quality by design (QbD) in chromatography.J Anal Pharm Chem.2017411078
     [Google Scholar]
  36. AgrawalR NaveenY. Pharmaceutical processing–A review on wet granulation technology.Int. J. Pharm. Front. Res.2011116583
     [Google Scholar]
  37. KristensenH.G. SchaeferT. Granulation: A review on pharmaceutical wet-granulation.Drug Dev. Ind. Pharm.1987134-580387210.3109/03639048709105217
     [Google Scholar]
  38. MesutB. ÖzsoyY. AksuB. The place of drug product critical quality parameters in quality by design (QBD).Turkish J Pharm Sci.20151217592
     [Google Scholar]
  39. FaisalA. Al-AbsiM. AlagbarriS. Al-NowihiM. Formulation by design approach for effervescent granules of vitamin C using statistical optimization methodologies.J. Appl. Pharm. Res.202084626910.18231/j.joapr.2020.v.8.i.4.62.69
     [Google Scholar]
  40. KaratzasA.A. PolitisS.N. RekkasD.M. Development of rapidly dissolving pellets within the Quality by Design approach.Drug Dev. Ind. Pharm.201743577077910.1080/03639045.2016.122057627625003
     [Google Scholar]
  41. JadavM PalV PanditH SutharN PithadiaA JhaLL Formulation, optimization and evaluation of nutraceutical effervescent granules containing curcumin and ascorbic acid by fusion technique using full factorial design.J. Nat. Remedies.202323415091516
     [Google Scholar]
  42. TengK. FuH. WuG. GongP. XieY. ZhouP. GongX. QuH. QbD-Guided Traditional Chinese Medicine Manufacturing Process: Development and Optimization of Fluid-Bed Granulation and Drying Processes for Xiaochaihu Capsules.AAPS PharmSciTech202324721010.1208/s12249‑023‑02663‑z37821749
     [Google Scholar]
  43. DesaiN. PurohitR. Development of novel high density gastroretentive multiparticulate pulsatile tablet of clopidogrel bisulfate using quality by design approach.AAPS PharmSciTech20171883208321810.1208/s12249‑017‑0805‑228550603
     [Google Scholar]
  44. SinghL. SharmaV. Quality by Design (QbD) approach in pharmaceuticals: status, challenges and next steps.Drug Deliv. Lett.2015512810.2174/2210303104666141112220253
     [Google Scholar]
  45. WalterM.T. WalterM.F. BrooksE.S. SteenhuisT.S. BollJ. WeilerK. Hydrologically sensitive areas: Variable source area hydrology implications for water quality risk assessment.J. Soil Water Conserv.2000553277284
     [Google Scholar]
  46. MayesT. Risk analysis in HACCP: burden or benefit?Food Control199892-317117610.1016/S0956‑7135(97)00055‑8
     [Google Scholar]
  47. NotermansS. MeadG.C. Incorporation of elements of quantitative risk analysis in the HACCP system.Int. J. Food Microbiol.1996301-215717310.1016/0168‑1605(96)00997‑X8856381
     [Google Scholar]
  48. CharooN.A. AliA.A. Quality risk management in pharmaceutical development.Drug Dev. Ind. Pharm.201339794796010.3109/03639045.2012.69906522757979
     [Google Scholar]
  49. BhoopB.S. RazaK. BegS. Developing “optimized” drug products employing “designed” experiments.Chemical Industry Digest.2013237076
     [Google Scholar]
  50. CundellT. Microbial contamination risk assessment in non‐sterile drug product manufacturing and risk mitigation.Pharmaceutical Microbiological Quality Assurance and ControlWiley201910.1002/9781119356196.ch2
     [Google Scholar]
  51. KhandkeS.S. MayesT. HACCP implementation: A practical guide to the implementation of the HACCP plan.Food Control199892-310310910.1016/S0956‑7135(97)00065‑0
     [Google Scholar]
  52. PazhayattilA.B. Sayeed-DestaN. Fredro-KumbaradziE. CollinsJ. Solid Oral Dose Process Validation.Springer201810.1007/978‑3‑030‑02472‑7
     [Google Scholar]
  53. HassanH. AdamS.K. AliasE. Meor Mohd AffandiM.M.R. ShamsuddinA.F. BasirR. Central composite design for formulation and optimization of solid lipid nanoparticles to enhance oral bioavailability of acyclovir.Molecules20212618543210.3390/molecules2618543234576904
     [Google Scholar]
  54. PandyaV.M. PatelJ.K. PatelD.J. Formulation and optimization of nanosuspensions for enhancing simvastatin dissolution using central composite design.Dissolut. Technol.2011183404510.14227/DT180311P40
     [Google Scholar]
  55. PaiR.S. SinghG. DeviV.K. Response surface methodology and process optimization of sustained release pellets using Taguchi orthogonal array design and central composite design.J. Adv. Pharm. Technol. Res.201231304010.4103/2231‑4040.9356522470891
     [Google Scholar]
  56. VuppalapatiL. CherukuriS. NeeliV. Reddy YeragamreddyP. Reddy KesavanB. Application of central composite design in optimization of valsartan nanosuspension to enhance its solubility and stability.Curr. Drug Deliv.201613114315710.2174/156720181266615072409435826205900
     [Google Scholar]
  57. SarojS. ShahP. JairajV. RathodR. Green analytical chemistry and quality by design: A combined approach towards robust and sustainable modern analysis.Curr. Anal. Chem.201814436738110.2174/1573411013666170615140836
     [Google Scholar]
  58. BansalS. BegS. GargB. AsthanaA. AsthanaG.S. SinghB. QbD-oriented development and characterization of effervescent floating-bioadhesive tablets of cefuroxime axetil.AAPS PharmSciTech20161751086109910.1208/s12249‑015‑0431‑926527606
     [Google Scholar]
  59. KelebE. VermeireA. VervaetC. RemonJ.P. Twin screw granulation as a simple and efficient tool for continuous wet granulation.Int. J. Pharm.20042731-218319410.1016/j.ijpharm.2004.01.00115010142
     [Google Scholar]
  60. PronkP. Infante FerreiraC.A. WitkampG.J. A dynamic model of Ostwald ripening in ice suspensions.J. Cryst. Growth20052751-2e1355e136110.1016/j.jcrysgro.2004.11.173
     [Google Scholar]
  61. SumitK. ShikhaT. DeepikaT. AshishB. A quantitative approach for pharmaceutical quality by design patterns.Inveti Rapid: Pharm Anal Qual Assur.2012418
     [Google Scholar]
  62. NamanS. MadhaviN. SinghB. MadanJ. BaldiA. Implementing risk-based quality by design for development and optimization of flavored oral disintegrating mini tablets.J. Drug Deliv. Sci. Technol.20216610279910.1016/j.jddst.2021.102799
     [Google Scholar]
  63. KumarS. BaldiA. Design of experiment based statistical optimization in life science research: An overview.Pharm Aspire.201343543
     [Google Scholar]
  64. QuelletC. SchudelM. RinggenbergR. Flavors & fragrance delivery systems.Chimia (Aarau)200155542142810.2533/chimia.2001.421
     [Google Scholar]
  65. ChudiwalV.S. ShahiS. ChudiwalS. Development of sustained release gastro-retentive tablet formulation of nicardipine hydrochloride using quality by design (QbD) approach.Drug Dev. Ind. Pharm.201844578779910.1080/03639045.2017.141311129198152
     [Google Scholar]
  66. KhariaA.A. SoniP. BarikS. Controlled Release Formulation of Tofacitinib Citrate Tablets Evaluated Using Quality by Design (QBD) Approach.J. Pharm. Res. Int.2021•••290306
     [Google Scholar]
  67. MangwandiC. AdamsM.J. HounslowM.J. SalmanA.D. An investigation of the influence of process and formulation variables on mechanical properties of high shear granules using design of experiment.Int. J. Pharm.2012427232833610.1016/j.ijpharm.2012.02.02922391113
     [Google Scholar]
  68. AlmutairyB.K. KhafagyE.S. AlalaiweA. AldawsariM.F. AlshahraniS.M. AlsulaysB.B. AlshetailiA.S. AlshehriS.M. FayedM.H. Enhancing the poor flow and tableting problems of high drug-loading formulation of canagliflozin using continuous green granulation process and design-of-experiment approach.Pharmaceuticals (Basel)2020131247310.3390/ph1312047333348779
     [Google Scholar]
  69. MamidiH.K. PalekarS. NukalaP.K. MishraS.M. PatkiM. FuY. SupnerP. ChauhanG. PatelK. Process optimization of twin-screw melt granulation of fenofibrate using design of experiment (DoE).Int. J. Pharm.202159312010110.1016/j.ijpharm.2020.12010133309834
     [Google Scholar]
  70. SoylakM. NarinI. BezerraM. FerreiraS. Factorial design in the optimization of preconcentration procedure for lead determination by FAAS.Talanta200565489589910.1016/j.talanta.2004.08.01118969885
     [Google Scholar]
  71. MahapatraA.P.K. SaraswatR. BotreM. PaulB. PrasadN. Application of response surface methodology (RSM) in statistical optimization and pharmaceutical characterization of a patient compliance effervescent tablet formulation of an antiepileptic drug levetiracetam.Future Journal of Pharmaceutical Sciences2020618210.1186/s43094‑020‑00096‑0
     [Google Scholar]
  72. GuidelineI.C.H.H.T. Pharmaceutical development Q8.Curr. Sep.2005411
     [Google Scholar]
  73. ArshadM.S. SedhainK. HussainA. AbbasN. MudassirJ. MehmoodF. IrfanM. LatifS. Quantification of carbon dioxide released from effervescent granules as a predictor of formulation quality using modified Chittick apparatus.Trop. J. Pharm. Res.202118344945810.4314/tjpr.v18i3.1
     [Google Scholar]
  74. RaniK.C. ParfatiN. EkajayaniN.I. KurniawanI.M.A. KristianiN.P.W. The development of Moringa leaves effervescent granules with effervescent agent of citric acid and sodium bicarbonate.Pharmaciana202111222524010.12928/pharmaciana.v11i2.20873
     [Google Scholar]
  75. SreekanthS.K. PalanichamyS. SekharanT.R. ThirupathiA.T. TABLETS OF NIFEDIPINE.Int. J. Pharma Bio Sci.201012
     [Google Scholar]
  76. DavisBS Quality by design.Risk management applications in pharmaceutical and biopharmaceutical manufacturing.Wiley20138910010.1002/9781118514399.ch5
     [Google Scholar]
  77. JAL-MOUSAWY Formulation and evaluation of effervescent granules of ibuprofen.Int J App Pharm.20191166669
     [Google Scholar]
  78. GuptaS KesarlaR OmriA Formulation strategies to improve the bioavailability of poorly absorbed drugs with special emphasis on self-emulsifying systems.ISRN Pharm.2013201384804310.1155/2013/848043
     [Google Scholar]
  79. ICH 2005Harmonized tripartite guideline, validation of analytical procedures: text and methodology.Proceedings of the international conference on harmonization of technical requirements for registration of pharmaceuticals for human use
     [Google Scholar]
  80. DesaiS.R. Quality by design-based formulation and evaluation of fast dissolving tablet of aspirin.Asian J. Pharm.20181201[AJP].
     [Google Scholar]
/content/journals/probiot/10.2174/0126666499346209250214075754
Loading
Quality by Design-based Formulation of Fizzy Granules Containing Probiotics
Curr. Probiotics 2, E26666499346209 (2025); https://doi.org/10.2174/0126666499346209250214075754
/content/journals/probiot/10.2174/0126666499346209250214075754
/content/journals/probiot/10.2174/0126666499346209250214075754
Loading

Data & Media loading...


  • Article Type:     Research Article
Keyword(s): 2D contour plots; Central composite design; fizzy drinks; fizzy granules; formulation by design; probiotics

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test